CD8A and neoplasm: A variety of therapeutic strategies, including prime-boost vaccination87 and infected cell vaccines,88 have extended survival in the B16-F10 model primarily through the induction of an anti-tumor adaptive immune response mediated in large part by cytotoxic CD8+ T cells.